Work

head and neck cancer Patient-reported outcomes (PROs) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab (nivo) or investigator’s choice (IC): CheckMate 141

Year: 2016

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdw435.30

Authors: K. Harrington, R.L. Ferris, J. Shaw, F. Taylor, M. Derosa, D. Turner-Bowker, L. Morrissey, K. Cocks, N. Kiyota, M. Gillison, J. Guigay

Institutions: Institute of Cancer Research, UPMC Hillman Cancer Center, Bristol-Myers Squibb (United States), Adelphi Group (United Kingdom), Kobe University Hospital, The Ohio State University, Centre Antoine Lacassagne

Language: English

Topic: Head and Neck Cancer Studies

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2587119044

FWCI:

Cites:

Cited by:

Related to: 10